A Study of Revaree Plus in People With Breast Cancer
Part of paid clinical trials in Basking Ridge, New Jersey.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07042581
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Hormone-receptor-positive Breast Cancer
- Stage 0 Breast Cancer
- Stage 0 Breast Carcinoma
- Stage I Breast Cancer
- Stage II Breast Cancer
- Stage II Breast Carcinoma
- Stage III Breast Cancer
- Stage III Breast Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Revaree Plus — DRUGRevaree Plus is a hyaluronic acid vaginal suppository
Study Details
The purpose of this study is to find out whether Revaree Plus is effective at improving vaginal health for people who are having symptoms of vaginal dryness during breast cancer treatment.
Key Dates
- Start date
- Jun 20, 2025
- Status verified
- Feb 2026
- Primary completion
- Jun 20, 2029
- Completion
- Jun 20, 2029
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Hormone-receptor positive breast cancer participantsParticipants will have a diagnosis of Stage 0-III Hormone-receptor positive breast cancer
Primary Outcome Measure
Change in Vaginal Assessment Scale from baseline to 8 weeks [ Time Frame: 8 weeks ]
Central Contacts
- Shari Goldfarb, MD646-888-5080
- Jeanne Carter, PhD646-888-5076
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent Only) | Basking Ridge | New Jersey | 07920 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Monmouth (Consent Only) | Middletown | New Jersey | 07748 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Bergen (Consent Only) | Montvale | New Jersey | 07645 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Cancer Center Suffolk-Commack (Consent Only) | Commack | New York | 11725 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Westchester (Consent Only) | Harrison | New York | 10604 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | Shari Goldfarb, MD 646-888-5080 |
| Memorial Sloan Kettering Nassau (Consent Only) | Uniondale | New York | 11553 | Shari Goldfarb, MD 646-888-5080 |
Find similar trials in Basking Ridge, NJ
By condition
By specialty
By research site
Memorial Sloan Kettering Basking Ridge (Consent Only)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Consent Only)· Middletown, NJMemorial Sloan Kettering Bergen (Consent Only)· Montvale, NJMemorial Sloan Kettering Cancer Center Suffolk-Commack (Consent Only)· Commack, NYMemorial Sloan Kettering Westchester (Consent Only)· Harrison, NYMemorial Sloan Kettering Cancer Center· New York, NY
Related Studies
- Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA MutationsRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPHASE2 · Recruiting · Proton Collaborative Group · Scottsdale, Arizona
- Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and LymphomaRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey